BLOCKADE OF EPIDERMAL GROWTH FACTOR RECEPTOR, CYCLOXYGENASE-2 (COX-2) AND MAMMALIAN TARGET OF RAPAMYCIN (M-TOR) IN ANIMAL MODEL OF LUNG CANCER

To explore the effectiveness and possible toxicity of the use of epidermal growth factor receptor inhibitor (EGFR Inhibitor), Celecoxib (COX2 inhibitor) and Sirolimus (m-TOR inhibitor) as single agents and drug combinations for the treatment of lung cancer in an experimental model. Lung cancer was i...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutical sciences and drug research 2016-11, p.281-286
Main Authors: Faria, T V, Faria, T M V, Barbosa, J, Lucio, S N., Ometto, F, Lima, J P S N, Serrano, S V, Cury, P M
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To explore the effectiveness and possible toxicity of the use of epidermal growth factor receptor inhibitor (EGFR Inhibitor), Celecoxib (COX2 inhibitor) and Sirolimus (m-TOR inhibitor) as single agents and drug combinations for the treatment of lung cancer in an experimental model. Lung cancer was induced in Balb-C mice by intraperitoneal injection urethane. Mice were treated with water (control) , Erlotinib (E) (50 mg/kg), Celecoxib (X) (50 mg/kg), Sirolimus (R) (2 mg/kg) given alone and in the following doublet and triplet combinations in the same dosages for 7 days. The number of pulmonary nodules in the combined treatment was significantly inhibited compared with control (p=0.010); E (p=0.028), EX (p=0.010), ERX (p=0.040) showed a smaller number of statistically significant nodules. Regarding coat changes we observe statistically significant differences among groups (p
ISSN:0975-248X
0975-248X
DOI:10.25004/IJPSDR.2016.080601